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Tetralogy of Fallot: Case-Based Update for the Treatment of Adult Congenital 
Patients 
Due to advancements in surgical technique and perioperative management, the number 
of patients with congenital heart disease (CHD) who are surviving until adulthood is 
growing.1 Tetralogy of Fallot (TOF) is the most common form of cyanotic CHD, with an 
estimated overall prevalence of 3,000 per one million births 2 and is considered to be 
one of the first congenital defects to be successfully repaired by cardiovascular 
surgeons. 3 As the outcomes of babies born with CHD, and specifically TOF, continue to 
improve, many countries have more adults living with TOF than children. With surgical 
correction, the 30- to 40-year survival rate is 85-90%.1 Consequently, new issues have 
emerged, including the assessment, diagnosis, and management of medical 
complications related to the CHD or surgical correction as well as issues found in the 
average aging population. For these reasons, it will become increasingly important for 
physicians, especially adult cardiologists, to understand adult CHD. 
 
TOF is a congenital cardiac anomaly associated with four presenting components, 1) 
perimembranous ventricular septal defect, 2) right ventricular outflow tract (RVOT) 
obstruction, 3) an overriding aortic root, and 4) right ventricular (RV) hypertrophy. 
[Figure 1] These findings are postulated to be caused by the anterior and cephalad 
migration of the infundibular septum. This displacement of the septum results in a 
misalignment of the infundibular septum with respect to the trabecular septum, 
narrowing the RVOT and creating a larger, overriding aorta and perimembranous 
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ventricular septal defect. RV hypertrophy develops as a consequence of the pressure 
overload caused by the RVOT and an overriding aorta. 
  
Several anatomical variants exist, including 1) TOF with pulmonary atresia with or 
without major aortopulmonary collaterals, 2) TOF with an absent, bicuspid or unicuspid 
pulmonary valve with or without pulmonary stenosis, 3) TOF with double outlet RV, and 
4) TOF with an atrio-ventricular septal defect. TOF is also associated with congenital 
anomalies, such as an atrial septal defect, patent foramen ovale, anomalous left 
anterior descending artery from the right coronary sinus with course anterior to the 
RVOT, right-sided aortic arch, branch pulmonary vein stenosis, partial anomalous 
pulmonary venous return, and left superior vena cava draining into the coronary sinus. 4 
When taking care of adults with TOF, it is important to know the anatomical variants and 
have the operative notes to help understand potential complications.  
 
Surgical treatment for TOF has advanced over time. Early surgical techniques involved 
the initial creation of several palliative shunts with the goal of inducing enlargement and 
growth of the hypoplastic pulmonary vessels and allowing a future complete repair of 
the complex anatomy. In 1944, Drs. Alfred Blalock and Helen Taussig along with 
surgical assistant Mr. Vivian Thomas developed a palliative procedure that involved the 
creation of a systemic to pulmonary shunt by connecting the subclavian artery to the 
pulmonary artery.5 This was known as the “Blalock-Taussig Thomas” (BTT) shunt, and it 
later became a palliative procedure for other cyanotic CHDs. In 1946, the creation of an 
anastomosis between the descending aorta and the left pulmonary artery was 
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described, known as the Potts shunt; however, this was later abandoned due to 
difficulty in closing the shunt at the time of complete repair. In 1962, the Waterston 
shunt created an anastomosis between the ascending aorta and the pulmonary artery. 
In 1966, the creation of an intra-pericardial anastomosis from the ascending aorta to the 
right pulmonary artery was described, known as the Cooley shunt. The Potts, 
Waterston, and Cooley shunts were central shunts and less likely to thrombose when 
compared to the relatively peripherally placed Blalock-Taussig Thomas shunt. In 1974, 
the modified Blalock-Taussig Thomas shunt was designed using a prosthetic tube graft 
interposed between the systemic subclavian artery and the pulmonary artery, instead of 
the direct anastomosis previously described.6  More recently, catheter-based balloon 
valvuloplasty with or without RVOT stenting has been used as the initial palliation in 
neonates with TOF to improve arterial oxygen saturation and pulmonary arterial 
growth.7 [Figure 2] 
 
Complete surgical repair for TOF was first performed in 1954 by a surgical team led by 
C. Walton lillehei at the University of Minnesota. 5 In 1955, at the Mayo Clinic, John 
Kirklin and associates performed an open repair of complex congenital heart defects 
including ventricular septal defect and TOF. In the 1970s, Bonchek and Starr at the 
University of Oregon evaluated the utility of surgical intervention in infancy and 
established the superiority of complete repair at an earlier age.8  
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 The timing of surgical repair has been controversial and evolving over the years. Before 
the 1970s, most patients with TOF underwent palliative surgery that involved the 
creation of a systemic-pulmonary shunt followed by delayed intra-cardiac repair. After 
the 1970s, primary intra-cardiac repair became the treatment of choice in both 
symptomatic and asymptomatic patients. In the current era, palliative shunts are only 
performed in those who are poor candidates for intra-cardiac repair in infancy. Intra-
cardiac surgical repair is usually performed electively in the first year of life.9 Early 
operations provide the benefits of alleviation of cyanosis, normalizing the patient's 
cardiovascular physiology, and minimizing secondary damage to the heart and other 
organs. Elective surgeries are typically performed between 3-11 months due to an 
acceptable operative risk, low incidence of significant arrhythmias and a long-term 
survival similar to that observed in the general population. 
 
A complete surgical repair consists of patch closure of the ventricular septal defect as 
well as relief of the RVOT, pulmonary valve, and pulmonary artery obstruction. Closure 
of the ventricular septal defect is usually performed with continuous polypropylene 
suture, polyethylene terephthalate material, or Gore-Tex patch through either a 
transventricular or transatrial approach. To relieve the right-sided obstruction, resection 
of the infundibular stenosis, with possible muscle resection is the most widely used 
method. This relief of the high afterload caused by the RVOT obstruction reduces RV 
hypertrophy that can predispose to RV failure and ventricular arrhythmias. In children, 
RV augmentation can be performed by placing a transannular patch. Due to rapid 
growth in infancy and childhood, every attempt is made to preserve the native 
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pulmonary valve when initial intra-cardiac repair is performed.9 If the pulmonary valve is 
abnormal, a pulmonary valvotomy or pulmonary valve resection may be necessary. On 
occasion, a RV to pulmonary artery conduit is required when unfavorable anatomy, 
such as pulmonary atresia, or an anomalous left anterior descending artery off the right 
coronary cusp that courses the RVOT (5-12% of cases), prevents safe surgical incision 
and complete repair. 5 
 
Over the years, materials used for surgical correction of RVOT obstruction have 
included placement of homografts, bovine jugular valved conduits, stentless valves, 
stented tissue valves, monocusp valves, mechanical valves, autologous pericardial 
valves and transcatheter pulmonary valves. In 2010, the FDA approved the Medtronic 
Melody Transcatheter Pulmonary Valve. This device is used as an adjunct to surgery 
when managing pediatric and adult patients with 1) existence of a circumferential RVOT 
conduit that was equal to, or greater than 16mm in diameter when implanted initially and 
2) dysfunctional RVOT conduits associated with clinical symptoms and either greater 
than moderate regurgitation or stenosis with mean RVOT gradient >35mmHg.9  
 
The long-term complications of TOF correlate to the year and specific surgical repair 
performed. To achieve relief of the RVOT obstruction, disruption of pulmonary valve 
integrity is often necessary by valvotomy or a transannular patch, which leads to varying 
degrees of pulmonary regurgitation. While pulmonary regurgitation can be well tolerated 
in childhood, it can progressively lead to decreased exercise capacity, RV dilatation, 
and ventricular arrhythmias, which increase the risk of sudden cardiac death (SCD). 
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Additionally, RVOT enlargement procedures result in scar formation and akinetic 
regions, which can lead to aneurysm formation. Other long term complications include 
branch pulmonary stenosis, residual atrial septal defect or ventricular septal defect, 
tricuspid regurgitation, RV dilatation and dysfunction, aortic dilatation, aortic 
regurgitation, and left ventricle (LV) dysfunction.10. Aortic dilatation at the level of the 
sinotubular junction, although frequent in patients with repaired TOF, has a low rate of 
progression and does not warrant a more aggressive approach or frequent assessment 
with cardiac magnetic resonance imaging (CMR).11 Evaluation of clinical status and 
potential complications must be periodically evaluated with imaging modalities.10 Adults 
with repaired TOF should be followed at least annually and more frequently depending 
on symptoms and complications of the repair. These patients are monitored with 
imaging modalities, electrocardiograms, cardiopulmonary stress tests, and occasionally 
may need diagnostic/therapeutic cardiac catheterizations.12 This review presents three 
clinical scenarios followed by evidence-based discussions of diagnostic imaging and 
strategies for managing complications of adults with TOF.  
 
Case 1. A 49-year old female with TOF presents with fatigue, malaise, and palpitations 
occurring with minimal exertion. She initially underwent a palliative left sided BTT shunt 
within the first two years of life (1969). At the age of four (1971), she underwent a 
surgical ventricular septal defect repair with a pulmonary valvotomy and transannular 
patch.  
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Physical exam revealed blood pressures of 122/78, heart rate of 68 bpm and pulse 
oxygenation of 99% on room air. The patient had a harsh 2/6 systolic murmur with a 4/6 
early diastolic murmur and single S2. Her electrocardiogram showed sinus rhythm with 
right bundle branch block (RBBB) with a QRS duration 188 msec. Her initial cardiac 
testing included an echocardiogram, cardiac magnetic resonance imaging (MRI) and 
cardiopulmonary stress test. Echocardiography revealed a severely dilated right atrium 
and RV, a large RVOT patch, no functional pulmonary valve with unrestricted 
pulmonary regurgitation, and normal left heart size with low normal LV systolic function 
of 45-50%.  Cardiac MRI showed RV ejection fraction of 22%, RV end-diastolic volume 
of 248cc/m2, RV end-systolic volume of 192 cc/m2 and LV ejection fraction of 49%.  A 
cardiopulmonary exercise test showed normal breathing reserve with a peak VO2 
(PkVO2) of 20.1 ml/kg/min indicating moderate functional impairment due to 
deconditioning. 
 
Discussion: Given the findings of her testing, her non-specific symptoms could be 
attributed to pulmonary valve insufficiency or RV enlargement.  What diagnostic tests 
may be useful to help differentiate the etiology? What are the indications for 
intervention? 
 
Despite the advances of early diagnosis, progression from a two-stage correction to 
single-stage repair in infancy and improved outcomes, the majority of adult patients with 
repaired TOF continue to have residual anatomic and hemodynamic abnormalities 
resulting in increasing rates of morbidity and mortality. Initially, relief of the obstructions 
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in the RVOT and pulmonary valve frequently results in pulmonary regurgitation, which 
initiates a cascade of pathophysiologic events leading to RV dilatation and subsequent 
dysfunction requiring pulmonary valve replacement (PVR) 1314. In addition to the 
pulmonary regurgitation, an adult with TOF needs evaluation for pulmonary artery 
stenosis, RVOT aneurysm, tricuspid regurgitation, residual ventricular septal defect, LV 
dysfunction, aortic valve regurgitation, and aortic dilatation for which multimodality 
imaging is necessary to provide a comprehensive assessment. 13  
 
Interpretation of the effects of RV remodeling after PVR on CMR and Echo require 
understanding of a few basic principles:  1) pulmonary regurgitation in adults with 
repaired TOF leads to progressive RV dilatation and progressive RV dysfunction, 2) RV 
dilatation is one of the leading risk factors for adverse cardiovascular events, and 3) 
timely prosthetic PVR with subsequent decrease in RV volumes decreases the risk of 
adverse events and improves long-term outcomes.15 RV volumes measured by CMR is 
currently used to guide pulmonary valve intervention. Most recently, Bokma et al. 
reported the best preoperative threshold to achieve mid-to-late RV normalization was 
RV end systolic volume <80 ml/m2. Patients with preoperative RV end systolic volume 
>95 ml/m2 were at an increased risk for suboptimal hemodynamic outcomes and 
adverse clinical events such as death, sustained ventricular arrhythmias and worsening 
heart failure. 16 Some experts caution on timing PVR solely based on RV volumes, as 
doing so, may be an oversimplification of a complicated issue, especially in an 
asymptomatic patient.17  
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Cardiac imaging with ECHO, CMR, cardiac computed tomography, and 
cardiopulmonary stress testing plays a pivotal role in the surveillance of patients, in 
identifying and measuring the anatomic and functional abnormalities, informing clinical 
decision making, and aiding in risk stratification. Echocardiography is the primary 
noninvasive imaging modality in patients with CHD due to its wide availability, low cost, 
portability, lack of exposure to harmful ionizing radiation, and high level of experience 
with this modality by the clinicians caring for patients with CHD.13 Two-dimensional, 
tissue doppler, three-dimensional, transesophageal, longitudinal strain and stress 
echocardiography can all assist in the evaluation of these adults. 2D echocardiography 
allows qualitative and quantitative assessment of the right heart, RVOT, pulmonary 
arteries, tricuspid valve, pulmonary valve, atrial and ventricular septa and aortic root. 
[Figure 3] Doppler echocardiography is essential for assessment of hemodynamic 
assessment such as RV pressure, degree of pulmonary and tricuspid regurgitation and 
diastolic dysfunction. Three-dimensional echocardiography can be used to quantitate 
RV volumes; however, the feasibility is low at 55% secondary to poor acoustic windows 
and challenges in defining the resolution between the endocardium and prominent 
trabeculations of the RV.18 Despite an underestimation when reconstructing 3D images 
compared to CMR, it is promising that future developments may enable 
Echocardiography to replace CMR for RV quantification.19 Transesophageal 
echocardiography can be used to guide interventional procedures or evaluate anatomy 
when transthoracic imaging is challenging.13  Preoperative strain echocardiography of 
the right and left ventricles has been shown to be predictive of postoperative ventricular 
function and New York Heart Association (NYHA) class after PVR and may be of 
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assistance in identifying optimal timing of surgery. Interestingly, in the adult TOF patient 
population, both the LV and RV strain is reduced after PVR. 20 
 
Supine exercise echocardiography can also play in role in determining the time of 
surgery by assessing hemodynamics during stress. In a study of 128 patient with TOF, 
fractional area change (FAC), tricuspid annular plane systolic excursion (TAPSE), and 
RV pressures were measured at rest and stress. It was feasible to measure these 
parameters at stress in 96% of the patients. The study was able to identify patients 
whose TAPSE and RV FAC did not increase with stress testing. However, the 
prognostic value of this needs to be further determined as the peak VO2 was the same 
in both the nonresponders and responders.21 
 
The main limitation of echocardiography lies in its ability to adequately imaging the 
complex, crescentic shaped right heart and the poor acoustic windows once a patient 
reaches adulthood.13 The importance of an accurate quantitative assessment of the RV 
size and function in adult patients with TOF requires the use of other imaging modalities 
such as CMR and computed tomography.  
 
CMR provides a comprehensive assessment of cardiovascular morphology and 
physiology independent of acoustic windows and without ionizing radiation, making it an 
ideal imaging modality for longitudinal follow up. It is the gold standard for quantification 
of ventricular size and function in patients with TOF due to its ability to provide accurate 
and highly reproducible measurements. [Figure 4] Additionally, this modality can detect 
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scar tissue in the ventricular myocardium defined as late gadolinium enhancement. 13 
Myocardial fibrosis is associated with adverse clinical outcomes such as ventricular 
dysfunction, exercise intolerance, neurohormonal activation, and clinical arrhythmia; its 
assessment is a key component of the evaluation by CMR.22 Novel techniques allow 
measurement of the extracellular volume fraction, a marker of extracellular matrix 
remodeling. The limitations of CMR include the cost, lack of portability, limited 
availability, artifacts from implants containing stainless steel, and relative 
contraindication in patients with a pacemaker or implantable defibrillator.13   
 
Although the focus of CMR in this patient population is often RV function, greater than 
20% of adults with repaired TOF have concomitant LV dysfunction. A study by Geva et 
al. showed that moderate or severe RV or LV systolic dysfunction, but not pulmonary 
regurgitation fraction or RV diastolic dimension, is an important factor associated with 
poor clinical status of long-term survivors of TOF repair. The close relationship between 
LV ejection fraction and RV ejection fraction suggests unfavorable ventricular-
ventricular interaction.23 Obviously, RV dilation and dysfunction results from pulmonary 
regurgitation. LV dilation and dysfunction results not only from tricuspid regurgitation, 
but also age at which palliative shunts were performed and aortic regurgitation. 
Measures to maintain or restore pulmonary valve function and to avoid RV 
aneurysm/akinesia are mandatory for preserving RV and LV function late after repair.24 
Thus, evaluation of LV dimensions and function is as critical in these patients as 
assessment of the RV.  
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Although RV volume load due to severe pulmonary regurgitation can be tolerated for 
many years, there is now evidence that the compensatory mechanisms of the RV 
myocardium ultimately fail. If the volume load is not eliminated or reduced by PVR, the 
dysfunction may be irreversible. Since CMR is the gold standard for assessing the 
anatomic and functional sequelae in patients with repaired TOF, it has a role in the 
risk/benefit analysis that occurs as part of the decision related to timing for PVR. The 
decision to insert a pulmonary valve relies on clinical assessment of symptoms and 
signs attributable to the cardiovascular system and measurements of pulmonary 
regurgitation, biventricular volume and function, shunt ratio, and several morphological 
criteria including an RVOT aneurysm, branch pulmonary artery stenosis, and severe 
aortic dilatation. Although other imaging modalities can obtain some of this data, CMR is 
best suited to reliably provide most or all of the necessary information with one single 
noninvasive examination that does not require exposure to ionizing radiation. 23 As 
discussed above, cardiac MRI provides suggestions for times of PVR based on RV 
volumes.  
 
Cardiac computed tomography is most commonly utilized as an alternative imaging 
modality in patients with absolute contraindications to CMR or in locations where CMR 
is not available.10 Electrocardiographically gated computed tomography provides 
excellent, usually submillimeter, spatial resolution which allows a very clear depiction of 
cardiovascular anatomy, especially useful for evaluation of small blood vessels such as 
the coronary arteries or distal pulmonary artery branches. Other advantages include the 
ability to perform cardiac computed tomography in patients with pacemakers and 
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implantable defibrillators as well as imaging of structures that are obscured on CMR by 
stainless steel metallic artifacts. Cardiac computed tomography has the inherent 
limitations of exposure to ionizing radiation, lower temporal resolution compared to 
echocardiography and CMR, and the inability to provide hemodynamic information on 
flow rate or velocity.13  
 
In addition to the multiple imaging modalities, biomarkers such as brain-natriuretic 
peptide (BNP) and its precursor, N-terminal pro-B-type natriuretic peptide, may be 
useful in screening for late complications in adult CHD. These biomarkers have firmly 
established diagnostic and prognostic value in acquired left heart failure. Heng et al. 
investigated the role of BNP in adult patients with repaired TOF. They found that 
neurohormonal activation; as evident by elevated circulating levels of natriuretic 
peptides, ET-1, and renin; was present in even asymptomatic patients with repaired 
TOF. During their investigation, a BNP level of >15 pmol/L  (equivalent to 126 pg/mL) 
was predictive of a fivefold increase in mortality. The authors suggested that the 
attributes of BNP in left-sided chronic heart failure may be appropriately extended to 
chronic RV pathology in repaired TOF, as ventricular myocyte stretch in this patient 
population is most commonly due to chronic volume loading with pulmonary 
regurgitation. SCD in repaired TOF remains a poorly mitigated outcome, with a long-
term estimated risk of 4 - 6%. BNP measurements may have a role in the clinical risk 
assessment and decision-making process in the risk evaluation for SCD and sustained 
arrhythmia; however, additional investigation is needed to delineate its use in CHD. 25 
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Cardiopulmonary exercise testing is a valuable tool in the assessment of patients with 
adult CHD. This non-invasive test allows for risk stratification with regards to morbidity 
and mortality as well as aids in the decision on the need and timing for therapeutic 
interventions. Peak VO2 and VE/VCO2 slope are well-established measures of exercise 
tolerance that have been shown to correlate with NYHA functional class, quality of life, 
and to be reliable independent predictors of morbidity and mortality, both in the setting 
of heart failure and CHD. Due to the inability to compare healthy volunteers to adults 
with CHD, who are known to have a reduced exercise capacity, Kempny et al. studied 
the distribution of exercise capacity across the spectrum of patients with adult CHD. 26 
[Figure 5] They found exercise capacity differs significantly across the spectrum of adult 
CHD with the lowest peak oxygen uptake (VO2) values and highest VE/VCO2 slope 
values in patients with Eisenmenger syndrome and complex CHD. Patients with aortic 
coarctation and transposition of the great arteries after arterial switch operation were 
found to have the highest peak VO2 values and lowest VE/VCO2 slope values. Even in 
the patients with adult CHD with the highest peak VO2 values, the average was 
significantly reduced when compared with healthy volunteers. In TOF, the reported 
average peak VO2 was 27.2 +/- 9.0 ml/kg/min and 22.5 +/-6.8 ml/kg/min in males and 
females, respectively.  The difference between genders was statistically significant. By 
comparing the disease-specific exercise capacity to that required for different physical 
activities and occupations, the authors provide information to guide therapy and assist 
in advising patients on physical activity and professional or career choices.26 
Additionally, cardiopulmonary exercise testing has been proposed as an objective 
exercise tolerance test to determine the optimal timing of PVR because 1) symptoms 
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are often volunteered late by patients but may be preceded by impairment in exercise 
testing and 2) impaired peak oxygen uptake on exercise testing is associated with a 
higher perioperative surgical risk. 27 
 
Diagnostic cardiac catheterization was once utilized universally in all patients with CHD 
but has been supplanted over the past 30 years by the multiple available non-invasive 
imaging modalities. Cardiac catheterization still retains a role when the non-invasive 
data is inconclusive or contradictory. In patients with right sided congenital heart 
abnormalities, catheterization provides direct hemodynamic assessment and allows for 
accurate measurement of shunts and calculation of pulmonary arterial resistance.28  
 
The cardiovascular testing discussed above is used to help guide the timing and need 
for PVR in patients with TOF and unrestricted pulmonary regurgitation. PVR can be 
performed using a transcatheter technique or surgically with one of many available 
bioprosthetic valves. The benefits of early PVR are in resolution in pulmonary 
regurgitation, 30-40% reduction in RV end-diastolic and end-systolic volumes, decrease 
in RV systolic pressure in those with pre-procedural RVOT obstruction, and consistent 
improvement in NYHA functional class although without a consistent change in 
objective exercise parameters or arrhythmia burden. Additionally, an unchanged RV 
and LV ejection fraction and slightly increased LV size are expected. 14 
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Despite investigations on timing, indications, techniques, and results for PVR, there is 
still considerable controversy on the best management strategy in asymptomatic 
patients. 23 In a study of over 1000 patients with TOF, the authors described the cardiac 
phenotype of patients defined as having good outcomes, as indicated by reaching age 
35 years without a PVR, being asymptomatic, and having normal exercise tolerance. 
These patients were found to have nearly normal right heart structure and function, 
including at most mild RVOT obstruction, normal pulmonary valve annulus diameter, no 
more than mild to moderate pulmonary regurgitation, high-normal or minimally dilated 
RV, no RVOT aneurysm, and normal RV systolic function. Out of the 50 patients 
randomly selected for in-depth evaluation, only 14 met criteria for good outcome. 
However, the authors concluded that despite being in a high volume study, the ability to 
accurately prognosticate remains poor, due to two patients in their “good outcome” 
group requiring a subsequent PVR. 29 Additionally, studies on patients with repaired 
TOF often exclude those with more complex anatomical variants or associated 
anomalies; therefore, the burden of residual disease and mortality in the overall TOF 
population is difficult to assess. With the advent of transcatheter valve therapies, there 
has been a lowering of the threshold for PVR. 
 
Pre-procedural assessment, frequently with multiple imaging modalities such as ECHO 
and CMR, is essential for evaluation of the RVOT to determine gradients, diameters, 
and morphology, and to allow successful percutaneous pulmonary valve implantation 
(PPVI). Based on indications proposed by the American Heart Association European 
Society of Cardiology and Association for European Pediatric Cardiology and Geva et 
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all, Figure 6 lists indications for surgical or transcatheter pulmonary valve intervention. 
12,14,30 In symptomatic patients, the guidelines suggest intervention when the RV systolic 
pressure is above 60 mmHg (tricuspid regurgitation velocity >3.5 m/s) or when there is 
moderate or severe pulmonary regurgitation. In asymptomatic patients, PPVI is 
indicated with severe RVOT stenosis and severe pulmonary regurgitation in the 
presence of decreased exercise capacity, progressive RV dilation, progressive RV 
systolic dysfunction, progressive tricuspid regurgitation, RV systolic pressure >80 
mmHg, or sustained atrial or ventricular arrhythmias. PPVI is indicated in dysfunctional 
surgical RVOT conduits with dilated diameters between 18 to 22mm and 23 to 26mm 
for the Melody and Sapien valves, respectively. PPVI is not currently recommended in 
native or patch-augmented RVOTs or in conduits less than16 mm in diameter. Absolute 
contraindications include active infection, occluded central veins, and coronary 
compression observed with RVOT balloon dilatation. Aortic or coronary angiography is 
routinely performed with simultaneous high-pressure balloon inflation in the valvular 
landing zone to assess if coronary flow is impaired by this maneuver, in order to avoid 
this potentially fatal complication (Ansari et al.). Future techniques and devices have the 
potential to expand routine PPVI eligibility to patients with native RVOTs, as well as 
those with RVOT diameters that are either smaller or larger than currently available 
devices, as patients presently having these features are requiring an open surgical 
approach. 28 In the subset of patients with CHD with native RVOT or RVOT patch 
repairs, there is a growing body of literature on the utility of commercially available 
valves used off-label. In one retrospective trial of 31 patients, Melody pulmonary valve 
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implantation in the native RVOT due to either stenosis or regurgitation was safe and 
feasible; however, there was a high stent fracture rate of 32% despite pre-stenting. 31 
 
Currently, there are three percutaneous valve options on the market. The Melody 
transcatheter pulmonary valve by Medtronic, Inc. consists of a bare-metal platinum-
iridium stent and a manually-sewn valved segment of bovine jugular vein. The Melody 
valve is available in diameters of 16 and 18 mm, which can be expanded to 18 or 20 
mm or 18, 20, or 22 mm, respectively. This device is delivered by a balloon-in-balloon 
technique. The Edwards Sapien Pulmonic transcatheter heart valve by Edwards 
Lifesciences is a tri-leaflet bovine pericardial tissue valve hand-sutured in a balloon-
expandable, radiopaque, stainless steel stent. It is available in 23 or 26 mm diameters 
and is delivered with the use of a guiding catheter and a single-balloon catheter. The 
Venus P Valve by Venus Medtech is another novel self-expanding percutaneous 
pulmonary device composed of a trileaflet porcine pericardial valve mounted on a 
covered nitinol stent frame. This valve ranges in size from 20 to 32 mm in diameter.28  
Data for the Edward Sapien valves is small but promising. A study was performed on 25 
patients, mostly with TOF, to evaluate outcomes after PPVI. The authors demonstrated 
a high technical success rate of 96%, improvement in intraprocedural hemodynamics 
including a decrease in the mean RV to systemic pressure ratio from 0.64 to 0.36 and 
RV to pulmonary artery gradient from 39 to 9 mmHg following valve replacement, and 
no clinically significant pulmonary regurgitation. One patient required elective surgical 
PVR for a high residual gradient, and one patient required re-intervention for severe 
pulmonary regurgitation at one year. At a mean follow up of 3.5 years, there were no 
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episodes of endocarditis and no stent fractures. There was preserved valve function 
during follow-up with no change in RV to pulmonary artery gradient nor pulmonary 
regurgitation severity. Based on the results, the authors concluded that the Edwards 
Sapien system is a viable and durable option for PPVI. 32 
 
Direct comparisons between surgical intervention and PPVI have not been performed. 
PPVI has the potential to avoid or delay open-heart surgery and its associated 
morbidity. Freedom from reintervention after PPVI has been reported above 90%, 80%, 
and 70% in follow-up periods of 1, 2, and 4 years, respectively. Factors associated with 
reintervention include a high post-PPVI residual RVOT gradient and stent compression 
or recoil after valve deployment. The most frequent complication of PPVI is fracture of 
the stent frame, reported in up to 30% of cases. Stent fractures are classified as type I, 
no loss of stent integrity; type II, loss of stent integrity; and type III, separation or 
embolization of the fractured segment. Type I fractures are usually managed 
conservatively and followed regularly, as they can progress to more advanced fractures. 
Type II and III fractures can be successfully treated with valve-in-valve procedures, 
although type III stent fractures may require surgical management in the case of distal 
strut embolization. 28 
  
At present, the problem responsible for late mortality and re-intervention or explantation 
in patients after PPVI is infective endocarditis. The risk of infective endocarditis in 
implanted homografts has been estimated at 2.4% per patient-year. Infective 
endocarditis occurs more frequently after PPVI than surgical PVR. Two large studies 
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comparing the incidence and outcomes of right-sided endocarditis in patients after 
surgical or percutaneous PV intervention showed 4.5-fold high risk of infective 
endocarditis after a percutaneous procedure. [Figure 8] Several factors explaining this 
difference have been proposed, include possible valvular damage before percutaneous 
implantation during crimping and balloon expansion, whereas surgical prostheses are 
placed directly into the RVOT without any manipulation.33 Additionally, a high residual 
RVOT gradient, the resulting turbulence, and in situ thrombosis have been implicated in 
the pathophysiology of post-PPVI endocarditis. 28 Dijck et al. reported that the Melody 
valve and Contegra had significantly higher incidence of infective endocarditis 
compared to the  Sapien valve, 7.5% and 20.4% vs. 2.4%, respectively. Infective 
endocarditis is also a significant threat for long-term conduit function. 34  
 
In addition to the pulmonary regurgitation, tricuspid regurgitation is a cause for concern 
in adults with repaired TOF; however, the management of functional tricuspid 
regurgitation is controversial. In a study by Woudstra et al., severe tricuspid 
regurgitation, although present in only a minority of patients, was associated with an 
increase in the composite outcome of adverse clinical events including tachyarrhythmia, 
progression of heart failure, and death. 35 In the study, patients with moderate tricuspid 
regurgitation and symptomatic (NYHA functional class >2) heart failure, mainly 
attributed to RV dysfunction and significant tricuspid regurgitation, were at highest risk 
for progression to severe tricuspid regurgitation.  Initially, surgeons tended to take a 
more aggressive approach to concomitant tricuspid valve annuloplasty at the time of 
PVR. Kogon et al investigated the effect of tricuspid valve intervention during PVR 
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surgery and noted that performing concomitant tricuspid annuloplasty not only requires 
several additional surgical steps, unnecessary for an isolated PVR, but also results in 
prolonged cardiopulmonary bypass time, which is associated with increased morbidity 
and prolonged lengths of stay in the setting of adult congenital heart surgeries.36 in a 
study of 65 patients undergoing PVR, there were no statistical differences between 
those patients undergoing concomitant tricuspid valve repair with PVR and those 
undergoing PVR alone in terms of the degree of tricuspid regurgitation and RV size six 
months after surgery. 37 Patients with moderate tricuspid valve regurgitation have also 
been observed to undergo significant improvement in tricuspid valve function and RV 
size following the first postoperative month after PVR, irrespective of concomitant 
tricuspid valve annuloplasty. Therefore a conservative approach to tricuspid valve 
annuloplasty should be taken in patients who undergo subsequent PVR after surgical 
palliation of TOF and congenital pulmonary stenosis.  
 
Case 1 Conclusion 
In summary, this patient presented with atypical symptoms which can be attributed to 
long-term complications of TOF. Based on multimodality imaging she was noted to have 
severe pulmonary regurgitation on echocardiography, a cardiac MRI with significant 
dilated RVEDV of 248cc/m2 and RVESV of 192cc/m2 and decreased Peak VO2 all 
supporting RV dilatation secondary to severe pulmonary regurgitation, for which she 
underwent PVR. Following the procedure, the RV end-diastolic volume decreased to 
168cc/m2 (33% reduction), and the RV end-systolic volume decreased to 131cc/m2 
(32% reduction). This proportional decrease in volumes resulted in an unchanged RV 
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ejection fraction of 22%.Use of various diagnostic modalities explained above helps 
cardiologists monitor for complications of TOF and determine indications for surgical or 
percutaneous intervention. 
 
Case 2. A 46-year old male with known diagnosis of TOF, recurrent atrial flutter that 
required radiofrequency ablation, amiodarone-induced hypothyroidism complete heart 
block with permanent pacemakers (PPM) and implantable cardioverter-defibrillators 
(ICD) in place. He presented with frequent episodes of palpitations and numerous 
shocks from his ICD. At age of 3, he underwent complete surgical repair of TOF, 
including pulmonary valvotomy. His condition was stable until age of 31 when he found 
to have progressive right heart enlargement from unrestricted pulmonary regurgitation, 
when he underwent a placement of a 29 mm Carpentier valve conduit in the pulmonary 
position and repair of the tricuspid valve. Twelve years later, at age of 42, he developed 
progressively worsening heart failure with pulmonary stenosis and insufficiency of the 
valve conduit resulting in implantation of a percutaneous Melody® valve (Medtronic Inc.) 
in the pulmonary position. His co-morbidities included hypertension, hyperlipidemia and 
elevated calcium score found on cardiac CT scan. His presentation to emergency 
department was consistent with acute decompensated heart failure with frequent shock 
from ICD. He had also gained weight and started to smoke cigarettes to alleviate stress. 
His EKG showed ventricular paced rhythm, and his ECHO showed increased RV size 
with low normal to mildly reduced RV systolic function. The peak velocity through the 
pulmonary valve conduit was 3 m/sec and mild aortic insufficiency and mild tricuspid 
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regurgitation. The left ventricle was dilated with LVEF of 45% and mildly dilated aortic 
root.  
 
Discussion: It is important to understand and assess the risk of atrial arrhythmias, 
ventricular arrhythmias, and SCD among patients with repaired TOF. What is the 
appropriate management of these arrhythmias? What are the indications for ICD 
implantation in such population?  
 
Following surgical repair for TOF, the majority of patients live well into their adult years; 
however, it is amongst the corrected congenital heart defects who are associated with 
the highest risk of ventricular arrhythmias and SCD.38 The annual incidence of SCD 
among adult patients with TOF varies with age but is generally believed to be 1-3% per 
year. 39There are several traditional risk factors for the development of SCD which can 
be placed into three broad categories: patient history (older age at the time of repair), 
electrophysiologic markers (complete heart block, QRS duration of ≥180 msec, 
premature ventricular contractions), and hemodynamic abnormalities resulting from 
chronic severe pulmonary regurgitation and other sequelae of surgical repair (i.e. 
increased RV pressures following repair). 40 Although some of these predictors are 
more sensitive than others, most of them have a low positive predictive value.41  
 
A large multicenter cross sectional study evaluated the arrhythmia burden in adults with 
repaired TOF. Sustained tachyarrhythmias were present in 43% patients, with 
increasing burden in older age patients. Although atrial arrhythmias were more 
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prevalent than ventricular arrhythmias, 20.1% vs. 14.6%, respectively; the single most 
common arrhythmia subtype is ventricular tachycardia (14.2%) followed by intra-atrial 
reentrant tachycardia (11.5%). 42 There is a 10-15 year period following corrective 
surgery in which tachyarrhythmias are less prevalent, followed by a steady decline in 
freedom from atrial and ventricular arrhythmias. It is important to note that while atrial 
fibrillation is uncommon and less prevalent than intra-atrial reentrant tachycardia in 
patients <45 years of age, the prevalence of atrial fibrillation exceeds that of intra-atrial 
reentrant tachycardia in patients more than 55 years of age. 42 [Figure 6] 
 
 
 
Intra-atrial tachycardia in TOF is predominantly a right-sided atrial arrhythmia where the 
tricuspid regurgitation is the predominant hemodynamic lesion, presumably leading to 
right atrial dilation and creating the substrate for atrial arrhythmogenesis.43 Atrial 
fibrillation, on the other hand, is associated with left atrial dilatation and LV 
dysfunction.44 Older age is associated with higher prevalence of atrial fibrillation; there is 
a steep rise in prevalence of atrial fibrillation earlier in patients with TOF compared to 
general population, age >45 years compared to >65 years, respectively. 42  In patients 
with TOF, treatment of atrial fibrillation with early radiofrequency ablation has shown 
high acute success rate, improvement in symptoms and lower chance for recurrence. 45 
A retrospective chart review among patients with CHD, who planned to have a cardiac 
operation and had pre-existing atrial arrhythmia, concomitant cardiac procedures with 
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Cox-maze procedure showed almost complete resolution of atrial arrhythmia 
postoperatively.46  
 
Among TOF patients, ventricular tachycardia accounts for the majority of ventricular 
arrhythmias likely due to hemodynamic and electrophysiological alterations that 
occurred in the congenital defect itself or due to the surgical correction of pre-existing 
lesion.47 Contrary to tricuspid regurgitation being the primary hemodynamic lesion result 
in atrial arrhythmias, pulmonary regurgitation is the primary hemodynamic lesion that 
results in ventricular tachycardia and sudden cardiac death. 43 Percutaneous pulmonary 
valve replacement has been shown to be protective against the development of 
recurrent arrhythmias. The use of catheter ablation for VT showed recurrence rate of 
34% at 3.8 years. 48 
 
Additionally, prolonged QRS duration and the rate of prolongation are important 
predictors of VT and recurrent SVT; however, the threshold is QRS duration > 160ms  
and  > 180 msec for VT and SVT, respectively. 44 in addition to being associated with an 
inducible ventricular tachycardia, QRS duration >180 msec is also associated with 
adverse arrhythmic events such as sudden cardiac death (SCD). 44 Palliative shunts 
have also been independently associated with inducible ventricular arrhythmias and 
appropriate ICD shocks in patients with TOF. Despite the increase in RV pressure that 
occurs from RVOT, the multicentered study by Gatzoulis et al. illustrated that isolated 
RVOT obstruction was not a predisposing factor for late clinical arrhythmias. Not 
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surprisingly, there is an increased prevalence of atrial and ventricular arrhythmias with 
increasing number of cardiac surgeries performed.42  
 
Approximately 20-25% of late deaths in adults with CHD occurs due to SCD. In TOF 
patients, the incidence is 2-6% per year.39 Prevention of SCD among TOF patients 
remains a major challenge, especially in reliably identifying the high-risk patients, and 
perhaps over-reliance on depressed LV function for primary prevention with ICD.49 The 
combination of moderate to severe LV systolic dysfunction (EF < 20%) and QRS >180 
ms had a strong positive and negative predictive value, 66% and 93%, respectively for 
predicting SCD. 41 A multicenter observational cohort study of 870 patients identified RV 
hypertrophy, LV or RV systolic dysfunction (EF <44%) and atrial tachyarrhythmias were 
predictors of SCD or sustained ventricular tachycardia in young adult patients with 
repaired TOF.40 LV longitudinal dysfunction, measured by LV strain and mitral annular 
plane systolic excursion, were also identified as predictive of SCD suggesting use of 
routine echocardiographic measures to estimate prognosis.50 
 
ICD therapy is reliable in sensing and terminating ventricular tachyarrhythmias as well 
as preventing SCD in high-risk patients. Among 121 patients with TOF, 31% had at 
least one appropriate ICD discharge, and 5.8% had inappropriate discharges yearly. 
The annual incidence of appropriate ICD shocks in primary and secondary prevention 
was 7.7% and 9.8%, respectively. Based on patient outcomes, hemodynamic and 
functional characteristics, Khairy et al proposed a risk score of six clinical variables to 
predict appropriate ICD shocks in primary prevention: presence of prior palliative shunt, 
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inducible sustained ventricular tachycardia, QRS duration >180 ms, ventriculotomy 
incision, nonsustained ventricular tachycardia, and LV end-diastolic pressure > 12 
mmHg. 51 
 
In addition to arrhythmogenic burden, it is well-known that the prevalence of heart 
failure among adults with CHD is higher compared to general population, and it is 
considered to be the leading cause of death among such population. 52 Diastolic 
dysfunction has been independently associated with ventricular arrhythmias and 
mortality in other disease states, such as post-coronary bypass surgery and chronic 
renal failure.53 The value of LV diastolic dysfunction in risk stratification of patients with 
TOF remains to be demonstrated; however, the ratio of early transmitral flow velocity 
(E) to early diastolic mitral annular velocity (e’), more specifically, E/e ratio greater than 
10 was a powerful predictor of ventricular arrhythmias. The association of diastolic 
dysfunction with increased RV afterload may contribute to the pathophysiology of RV 
failure, particularly in the setting of pulmonary regurgitation with chronic volume 
overload.42 
 
Due to the advances in cardiothoracic surgery and medical management of patients 
with CHD, there are currently more adults living with adult CHD than children, and this 
number is expected to grow at a rate of approximately 5% per year.54 As these patients 
age, they are prone to same diseases as the adult non-CHD populations, such as 
obesity, type 2 diabetes mellitus, and myocardial infarction. Because of the increased 
survival and an increasing impact of acquired heart disease, myocardial infarction is the 
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leading cause of mortality in patients with non-cyanotic adult CHD. In a prospective 
randomized trial aimed to investigated the safety of exercise among adult patients with 
repaired TOF. Results showed exercise was not proarrhythmic in patients with repaired 
TOF with no previous history of sustained ventricular arrhythmia determined by Holter 
monitor. Actually, exercise seemed to provide a beneficial effect on ventricular 
arrhythmias, as it showed a significant reduction in runs of nonsustained ventricular 
tachycardia over the course of the 12 week exercise program. As exercise capacity in 
adults with CHD is lower than in the general population and is it has predictive power of 
morbidity and mortality, an overly restrictive approach to exercise training due to fears 
or misconceptions regarding exercise training might have an undesirable effect.38 
 
Obesity is a prominent comorbidity in patients with adult CHD due a lack of physical 
activity and high caloric intake, and according to a study evaluated patients with  adult 
CHD, 54% of them were overweight.55 Health care providers should evaluate 
anthropometry at every clinic encounter, assess diet and the level of physical activity, 
measure the blood pressure, fasting lipid panel, and glucose.54 While physical activity 
guidelines in adults with congenital heart disease is limited, dynamic rather than static 
exercises have been encouraged 30 In patients with successfully repaired heart defects 
without residual sequelae, recommend performing 150 minutes of moderate physical 
activity or 75 minutes of vigorous physical activity, discuss restraints, if any, related to 
arrhythmias and how to incorporate physical activity into daily schedules. 56-57 High risk 
patients such as those with advanced biventricular dysfunction and marked ascending 
aortopathy should participate in low-intensity activities. 58 In adults with CHD, physical 
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activity not only increases the threshold for maximal oxygen consumption, peak oxygen 
consumption, peak oxygen pulse, exercise tolerance, total treadmill time, heart rate 
recovery, and walking distance, but also enhanced self-esteem, confidence, improved 
quality of life and reduction in psychological stress.54 Encouraging dietary changes such 
as timely meals and lower-calorie nutrient dense foods will also be beneficial in weight 
loss and achieve normal BMI. 
  
As children with adult CHD grow into adulthood, they are also at risk for engaging in 
alcohol, tobacco, and other substance abuse. About 28% of adolescents and 54% of 
young adults with CHD reported substance abuse in the prior 30 days.59 Health care 
providers should take the opportunity at every encounter to educate about the 
deleterious effects of alcohol, tobacco, and energy supplements on the patient’s 
cardiovascular health.54  
 
Our patient had been gaining weight, had a BMI of 36 suggestive of obesity and had 
started to smoke. In addition, to address organic problems such as arrhythmias, it was 
also important for us as healthcare providers to discuss lifestyle choices and minimize 
risk factors for acquired heart disease.  
 
In summary, adults with repaired TOF are at high risk of atrial and ventricular 
arrhythmias as well as complications of acquired heart disease and other comorbidities. 
The patient in the case at age 46 had both atrial and ventricular arrhythmias. His atrial 
arrhythmias were most likely related to this enlarged right side and significant tricuspid 
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regurgitation which was intervened on with a tricuspid ring in his 30s. His atrial flutter 
was treated with radiofrequency ablation, and he started on amiodarone which was 
eventually stopped from amiodarone-induced hypothyroidism. In regards to his frequent 
episodes of ventricular arrhythmia, his native QRS was >180 msec and had depressed 
LV systolic function < 50% both of which, carries increased risk of having ventricular 
arrhythmias. This led to very frequent episodes of appropriate ICD shock to eliminate 
his arrhythmia. Unfortunately, these ICD shock significantly impaired the patient quality 
of life of our patient and created a substrate for post-traumatic stress disorder. 
Eventually, the patient decided to turned off his ICD with the understanding of risks 
associated with that. In addition to managing risk of arrhythmias, healthcare providers 
should also discuss risk of comorbidities and discuss lifestyle modifications to minimize 
risk of obesity, coronary artery disease, and substance abuse. 
 
Case 3. A 32-year-old female with TOF who had complete surgical correction including 
pulmonary valvotomy at infancy presented for pre-pregnancy counseling. She has been 
unable to conceive with her husband for the past 12 months, and the couple considered 
in-vitro fertilization. ECG showed normal sinus rhythm, RBBB and QRS duration of 132 
msec. She underwent a cardiopulmonary exercise testing (CPET) which showed a peak 
oxygen uptake (PkVO2) of 31 mL/kg/min. Her echocardiogram and cardiac MRI 
supporting the finding of normal LVEF of 64%; dilated RV with RVEDV of 177 cc/m2 
and RVESV of 95cc/m2; unrestricted severe pulmonary regurgitation and dilated sinus 
of Valsalva of 38 mm x 37mm. Cardiac catheterization supported the above finding and 
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additionally showed normal pulmonary pressures and no evidence of aortopulmonary 
collaterals. 
 
Discussion: Among patients with TOF, what is the clinical impact of pregnancy on 
mother and fetal heart? What are the peripartum cardiac complications that could occur 
in the pregnant patient with TOF, specifically on the aorta and RV? What are the 
morbidity and mortality risk to the baby and the mother? What is the likelihood of 
transmission of CHD to the baby? Are there additional risks for pursuing infertility 
treatment? 
 
Maternal organs undergo several significant physiological alterations during pregnancy. 
Maternal blood volume begins to increase with the early hormonal changes of 
conception and peaks around 32 weeks of gestation. The overall increase in blood 
volume during pregnancy is approximately 40% for a singleton and 67% for twin 
gestation. Both plasma volume and red blood cell mass contribute to the hypervolemia. 
Estrogen has a key role in plasma volume expansion and promotes sodium and water 
retention by upregulating the production of angiotensinogen, renin, and aldosterone. 
The disproportionate expansion of plasma volume relative to red blood cell mass 
contributes to the physiological anemia of pregnancy.60 The average BNP in a healthy 
pregnant woman is approximately twice that of nonpregnant control subjects, rising 
early in pregnancy and remaining elevated throughout gestation until 72 hours following 
delivery. Adverse maternal cardiac events have been associated with high BNP 
concentrations (>100 pg/mL), but its use as a negative predictive indicator appears to 
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be of most value. In one series, the negative predictive value of NT-pro-BNP <128 
pg/mL at 20 weeks gestation exceeded 95%.61  
  
The vasculature undergoes remodeling to accommodate the increased blood volume 
associated with pregnancy. Pulmonary vascular resistance declines by approximately 
24% by 8th week of gestation and remains stable over the remainder of the pregnancy. 
The decrease in pulmonary vascular resistance accommodates the near 50% increase 
in pulmonary flow; thus, the mean pulmonary artery pressure remains unaltered in a 
normal pregnancy. The systemic vascular resistance also decreases during pregnancy, 
resulting in a decrease in preload and afterload. Within eight weeks after the last 
menstrual period, systemic vascular resistance is reduced by approximately 30%, 
reaching its lowest value around 24 weeks of gestation. Fall in systemic vascular 
resistance is associated with a 10 to 15 mmHg reduction in the diastolic pressure at 20 
to 24 weeks gestation. After that point in time, systemic vascular resistance, and thus 
diastolic blood pressure, begins to increase again, approaching preconception levels by 
term. Cardiac output increases 30-50% in a singleton pregnancy with an additional 10-
20% increment in a twin pregnancy. Maternal posture can significantly affect cardiac 
output, especially after 20 weeks of gestation when the gravid uterus compresses the 
inferior vena cava and pelvic veins.61 
 
Tidal volume increases 40% with a proportional rise in minute ventilation. This 
physiological hyperventilation is greater than the increase in oxygen consumption and 
accounts for the breathlessness that begins in early pregnancy. Maternal heart rate 
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progressively increases 10 to 20 beats per minute over pregestational rates, peaking in 
the late second or early third trimester. Pregnancy also lowers the threshold for isolated 
rhythm disturbances, including atrial and ventricular premature beats and re-entrant 
supraventricular tachycardia. Moreover, during pregnancy, there is a fall in the oncotic 
pressure due to a 12-18% decrease in circulating albumin concentrations with the 
lowest levels at approximately 24 weeks of gestation. This decline in oncotic pressure in 
addition to an increase in femoral venous pressure due to uterine compression of the 
inferior vena cava produces the edema of pregnancy. The lowered oncotic pressure can 
become hemodynamically significant, especially when combined with generous 
administration of crystalloid, making patients more susceptible to pulmonary edema.61 
  
Since pregnancy requires a complex set of adaptations of the cardiovascular system, 
which may be particularly demanding in the context of underlying heart disease, 
preconception care, and counseling is of fundamental importance.  The woman and her 
partner should have a clear understanding of the potential risk of pregnancy for her and 
her offspring. For the woman contemplating an immediate pregnancy, a more focused 
discussion is required about pregnancy risk and the potential need to undergo 
diagnostic cardiovascular testing. 61 According to European Society of Cardiology 
Guidelines on the management of cardiovascular diseases during pregnancy, all 
patients should have a pre-pregnancy assessment including a medical history, 
echocardiography, and exercise testing.62 An exercise test before pregnancy where a 
woman achieves <70% of expected workload, shows a drop in arterial pressure or a 
decrease in oxygen saturation will identify those at risk of developing symptoms or 
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complications during pregnancy and further evaluation will be needed before 
conception.62 
 
Overall, women with CHD during tolerated pregnancy well; however, they are at higher 
risk for potential cardiovascular complications during pregnancy, including heart failure, 
arrhythmias, stroke, death, thromboembolism, progressive aortic root dilation, RV 
dysfunction and PV regurgitation.61 These risk increases in the presence of underlying 
heart defect such as ventricular function, valvular function, functional class, and 
cyanosis. 62 The rate of miscarriages and maternal complications increases with more 
complex congenital heart diseases, and patients who experience complications during 
pregnancy may also be at higher risk of late cardiac events after pregnancy.61 
Historically, an emphasis was placed on quantifying and reducing maternal cardiac risk.  
A study by Ouyang et al. assessed obstetrical outcomes in 112 pregnancies in 65 
women with CHD. 33% of pregnancies were associated with adverse obstetrical events, 
such as preterm labor and  delivery (21%), postpartum hemorrhage (14%), premature 
rupture of membranes (10%), pregnancy-induced hypertension and preeclampsia (3%), 
placental abruption (3%) and intrauterine fetal demise (2%).63 Those who delivered 
vaginally but avoided Valsalva, as often recommended for high-risk patients, 
experienced a higher rate of postpartum hemorrhage and third- or fourth-degree 
lacerations. Adverse fetal and neonatal outcomes complicate 15-39% of pregnancies. 
Frequent complications include premature birth, small-for-gestational-age birth weight, 
respiratory distress, and intraventricular hemorrhage. Reported independent risk factors 
for fetal and neonatal complications include NYHA functional class above II, or cyanosis 
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during the baseline visit and left heart obstruction. Additional risk factors include older 
maternal age, multiple gestations, maternal smoking history, heparin/warfarin during 
pregnancy, history of premature delivery, antepartum bleeding after 12 weeks gestation 
and febrile illness. 64  
 
There are several predictive scores when evaluating a TOF patient requesting 
counseling prior to pregnancy. In the CARPREG study, Siu and colleagues 
prospectively assessed predictors of adverse events in a cohort of 562 pregnant women 
with various forms of heart disease, including congenital, and determined four risk 
factors for a combined cardiovascular endpoint resulting in cardiac death, stroke, 
pulmonary edema, or arrhythmia. The risk factors identified with NYHA functional class 
III and IV were: LV ejection fraction <40%, left heart obstruction (mitral valve <2.0cm2, 
aortic area <1.5cm2, or peak LV outflow tract gradient >30 mmHg), and history of a 
cardiac event prior to pregnancy such as arrhythmia, stroke, transient ischemic attack or 
pulmonary edema. From this data, a risk index was generated. The rate of primary 
cardiac events was 4%, 27%, and 62% in women with zero, one, and two or more risk 
factors, respectively. 65 The predictors of maternal cardiovascular events identified in 
CHD in the ZAHARA study includes a history of an arrhythmia event, baseline NYHA 
functional class >II, left heart obstruction (aortic valve peak gradient >50 mmHg), 
mechanical valve prosthesis, moderate/severe systemic atrioventricular valve 
regurgitation, moderate/severe sub-pulmonary atrioventricular valve regurgitation, use 
of cardiac medication pre-pregnancy, and repaired or unrepaired cyanotic heart 
disease.66 A prospective study among pregnant women with CHD subsequently 
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extended these findings by identifying a prior smoking history and decreased 
subpulmonary ventricular systolic function and severe pulmonary regurgitation as 
additional independent risk factors.64 The ESC Guidelines place patients with severe 
systemic ventricular dysfunction, as defined by a LV ejection fraction <30% or NYHA III-
IV, into World Health Organization risk class IV, indicative of those in whom pregnancy 
is contraindicated.62 
 
Women with repaired TOF usually tolerate pregnancy well with cardiac complications, 
commonly arrhythmias, and heart failure, occurring in up to 12% of patients. Other 
potential cardiac complications include thrombo-embolism, progressive aortic root 
dilatation, and endocarditis.62 RV dysfunction and moderate to severe pulmonary 
regurgitation are risk factors for cardiovascular complications, and pregnancy may be 
associated with a persisting increase in RV size. In symptomatic women with marked 
dilatation of the RV due to severe pulmonary regurgitation, pre-pregnancy PVR using a 
homograft should be considered. In the majority of pregnant patients with repaired TOF, 
follow-up every trimester is sufficient; however, there are clinical situations that may 
necessitate more frequent evaluations. In women with severe pulmonary regurgitation, 
monthly or bimonthly cardiac assessment with echocardiography is indicated. If RV 
failure occurs during pregnancy, treatment with diuretics should be started, and bed rest 
advised. Transcatheter valve implantation or early delivery may be considered in those 
who do not respond to conservative treatment.62 Minimizing fetal radiation exposure can 
be accomplished by shortening fluoroscopic time, reducing the x-ray tube voltage, 
reducing the tube current, reducing the imaging frames per second to the lowest setting, 
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using single-plane fluoroscopy, and avoiding cineangiography. Internal jugular or 
subclavian/radial approaches are preferable, avoiding femoral access if possible. 
Transcatheter interventional procedures are rarely performed during pregnancy, and if a 
procedure is considered, the patient should be referred to an adult CHD center with 
interventional expertise in the treatment of such conditions. Overall, patients with 
repaired TOF are classified as World Health Organization risk class II, which represents 
women who might have a small increase in maternal mortality or a moderate increase in 
morbidity with pregnancy. 61 Unrepaired TOF and the presence of morphologic 
pulmonary artery abnormality; including hypoplastic or disconnected pulmonary artery 
or ductal origin of the pulmonary artery; are independently predictive of low infant birth 
weight. 67 
 
Patients with surgically corrected TOF usually tolerate pregnancy well; however, an 
already compromised RV may be susceptible to further pregnancy-induced volume 
loading with right heart failure. Through ventricular-ventricular interactions, RV volume 
overload may impair LV diastolic compliance and contractility resulting in acute left heart 
failure. Additional right-sided volume load may also predispose to arrhythmias. The 
goals in caring for a patient with surgically repaired TOF should include addressing the 
severe pulmonary regurgitation prior to pregnancy, avoid excessive fluid administration, 
avoid increases in pulmonary vascular resistance through the prevention of hypoxia and 
hypercarbia, and maintenance of sinus rhythm. 64In some series, TOF is the single most 
common form of moderate CHD in pregnant women. Despite the absence of overt 
cardiac symptoms, patients remain at risk for maternal and fetal complications. Residual 
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pulmonary regurgitation, although usually well tolerated in pregnant women with TOF, 
has been associated with an increased risk of fetal loss, symptomatic right heart failure, 
left heart failure, and arrhythmias. An increase in RV size may also persist after 
pregnancy. 64 There was no relationship between pregnancy and change in aortic root 
dilation. 68 Our patient had aortic root of 3.7 cm, which is considered to be dilated 
according to her age and body metrics.  
 
Women with moderate CHD, which includes TOF, should be managed and delivered in 
specialized centers with multidisciplinary expertise and experience in CHD, obstetrics, 
anesthesiology, and neonatology. A coordinated care pathway for supervision of 
delivery and the postpartum period should be developed and in place by the third 
trimester and made available to all caregivers and the patients. The plan for delivery 
may change as the pregnancy evolves, but should include whether labor or cesarean 
delivery is indicated, and the recommended approach to labor analgesia or surgical 
anesthesia. In planning an obstetric anesthetic, it is important to understand the 
patient’s cardiovascular anatomy and physiology, labor and delivery, hemodynamic 
alterations induced by different anesthetic techniques, and cardiac and obstetric 
complications for which the patient may be at risk. At the time of delivery, the preferred 
mode is vaginal.62 Labor causes important hemodynamic changes, including elevations 
in heart rate, central venous pressure, and cardiac output. The maternal position has an 
effect on the degree of changes that are seen in these parameters. In the supine 
position, contractions are associated with a 15% rise in cardiac output, while cardiac 
output rises only 8-11% in the lateral position. Additionally, uterine contractions 
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augment maternal cardiac output as a result of enhanced sympathetic activity and 
expulsion of uterine blood into the central venous circulation. During a contraction, the 
uterus expels up to 400 mL of blood into the central venous circulation, leading to a rise 
in central venous pressure, right atrial pressure, cardiac output, and arterial pressure. 
The labor-induced augmentation of cardiac output is attenuated by effective epidural 
anesthesia. The increase in arterial pressure associated with labor can be attenuated by 
effective pain control and lateral tilting of the patient. Epidural anesthesia can reduce 
the return of blood to the heart due to venodilatation, so caution should be used in 
dosing.61 Postpartum, maternal cardiac reserve is challenged by an increase in preload 
due to inferior vena cava decompression and extrusion of blood from the contracted 
uterus into the inferior vena cava. Augmented venous return increases maternal cardiac 
output by 60-80% after vaginal delivery. This abrupt risk in cardiac output dissipates to 
prelabor values within one hour postpartum and falls further over the following 24 
weeks. Mean arterial pressure can be elevated for one or two days postpartum before 
declining over the next two weeks.  
One frequently asked question by potential mothers with CHD, is the estimated risk an 
offspring will be affected with a congenital abnormality. The role of genetic counseling 
has increased in relation to the growth of available genetic information, noninvasive 
imaging to identify subtle defects, and the availability of targeted genetic testing. 
Advances in genetics now allow for accurate estimation of transmission risks for many 
forms of CHD, whether isolated, syndromic, or familial. Typically, the risk of 
transmission to the offspring of affected mothers is in the order of 2-5%, which is a ten-
fold increase in risk compared with the general population. Concordance rates may be 
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higher in specific subtypes, including left-heart obstruction (8%) and deletion syndromes 
such as 22q11. Particularly high-risk groups include interrupted aortic arch, truncus 
arteriosus, and TOF, where the prevalence of 22q11 deletion may be as high as 50, 14, 
and 16%, respectively Offspring of mothers with TOF, in general, have a reported 
incidence of CHD of approximately 3.1%.67 In addition to genetic counseling, women 
with CHD should be offered fetal echocardiographic evaluation between 18 and 22 
weeks of pregnancy.64  
 
Before considering the possibility of assisted reproductive technologies (ART), the first 
question to address is whether a pregnancy would be possible without having an 
inappropriate risk to the mother or the neonate. The specific risk of multiple gestations is 
associated with a further hemodynamic burden for the mother and must be taken into 
account. Multiple pregnancies are frequent in ART usage with the incidence of twins 
with in vitro fertilization-conceived pregnancies being approximately 27%. The extent to 
which women are able to cope with the hemodynamic challenges imposed by 
pregnancy, especially multiple pregnancies, depends on the nature, severity, and 
current status of the underlying heart condition. As stated previously, the overall 
increase in blood volume during pregnancy is approximately 40% for a singleton and 
67% for twin gestation. The large increase in blood volume is a hemodynamic stressor, 
especially in a twin gestation, that must be considered when considering ART. 69 ART 
refers to all fertility treatments in which oocytes and sperm are handled with the goal of 
achieving pregnancy. For both in vitro fertilization and intracytoplasmic sperm injection, 
the woman's uterus and hormonal environment are primed for oocyte retrieval and 
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endometrial implantation through the use of exogenous hormones. To control the 
menstrual cycle and ovarian maturation, oral contraceptives or gonadotrophin-releasing 
hormone analogs are given during the menstrual cycle before the ART attempt. 
Gonadotrophins, human menopausal gonadotrophins, human chorionic gonadotrophin, 
or clomiphene citrate are then delivered in order to achieve follicle stimulation over the 
first 1 to 1.5 weeks of the cycle. Once the target follicle size and estradiol level are 
reached, human gonadotrophin is administered in order to initiate ovulation, followed by 
oocyte retrieval. After in vitro fertilization and transfer of the embryo into the uterus, 
estrogen, progesterone, human gonadotrophin may be given in the luteal phase and up 
to the end of the first trimester in order to encourage implantation and endometrial 
development. The estrogen levels resulting from ovarian stimulation lie well above 
normal physiological levels. 69All ART results in pronounced changes in endogenous 
hormone levels, with potential impact on several components of the cardiovascular 
system. Estradiol suppression in response to gonadotrophin-releasing hormone 
agonists is associated with an increase in blood pressure and systemic vascular 
resistance. Conversely, an increase in estradiol levels during ovulation stimulation 
induces a decrease in mean arterial pressure and peripheral vascular resistance, as 
well as an increase in cardiac output. Changes in hormone levels also affect the 
coagulation cascade with a shift towards a coagulative state with increases in von 
Willebrand factor, Factor VIII, Factor V, and fibrinogen and increased activated protein 
C resistance which creates a prothrombotic state. There is also a reduction in important 
fibrinolytic agents such as tissue plasminogen activator. In addition, thrombin generation 
and fibrin formation are augmented in ART patients. In the majority of patients without 
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CHD, these hemodynamic and hemostatic changes have few clinical consequences; 
however, the statistics of consequence in CHD is unknown. 69  
 
Risk stratification and counseling are important for women with heart disease 
undergoing ART. ART, such as in vitro fertilization, in particular, are associated with an 
increased risk of gestational hypertension and pre-eclampsia. Moreover, multiple 
pregnancies and advanced maternal age further increase the risk of hypertensive 
complications. Rates of venous thromboembolism during pregnancy are also higher in 
women undergoing in vitro fertilization. The World Health Organization classification is a 
valuable tool for this purpose, and fertility treatments should not be performed in women 
who meet WHO class III and IV criteria. As stated previously, women with repaired TOF 
are considered World Health Organization class II and present only a small increased 
risk of maternal mortality or moderate increase in morbidity, and thus, are capable of 
undergoing ART. 
 
Case 3 Conclusion 
At the age of 32 years, with excellent exercise capacity despite severe pulmonary 
insufficiency and significantly increased right heart volumes, it was important to discuss 
our patient’s and her baby’s risk of morbidity and mortality especially if she was going to 
use ART. She was at risk of atrial arrhythmias secondary to right heart dilation and 
increased volume during pregnancy and changes in hemodynamics with ART all 
discussed above. It was decided that patient undergo a PVR before pregnancy to 
decrease morbidity. She underwent PVR with a 25 mm bioprosthetic valve with 
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arterioplasty of the main and left pulmonary arteries.  In the following year, she utilized 
assisted-reproductive therapy to conceive and give birth to a healthy child. Peripartum 
and postpartum follow up was arranged, no intervention was necessary during 
pregnancy. 
 
Conclusion 
Due to improvements in surgical technique and perioperative management, the number 
of patients with TOF surviving into adulthood continues to grow. The increasing 
prevalence necessitates the need for all cardiologists to understand that the long-term 
complications and risks in this particular patient population are dependent upon the 
congenital abnormalities present at birth and the surgical procedures performed in the 
repair of those abnormalities. In the long-term care of patients with TOF, a team 
approach should be utilized to address the complications of RV dilatation, arrhythmias, 
and assistance during reproductive years. 
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ABBREVIATIONS USED: 
ART, CMR, CHD, CPET, ECHO, FAC, ICD, LV, NYHA, PPVI, PVR, RBBB, RV, RVOT, 
TAPSE, TOF 
 
FIGURES 
Figure 1: Anatomical drawing of Tetralogy of Fallot 
Figure 2: Timeline of shunts 
Figure 3: 4 chamber view on Echocardiogram 
Figure 4: Cardiac MRI image of RV  
Figure 5: Exercise capacity in adults with congenital heart disease 
Figure 6: Indications for Pulmonary Valve Replacement 
Figure 7: Right sided endocarditis on Echocardiogram 
Figure 8: Prevalence of arrhythmias with age 
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Figure 1: Anatomical drawing of Tetralogy of Fallot 
 
 Adapted from https://daughteroftime.wordpress.com/2014/06/03/think-pink-questions-
answered/. Date accessed: Feb 25, 2018  
53 
Figure 2: Timeline of shunts 
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Figure 3: 4 chamber view of heart by Echocardiography 
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Figure 4: Cardiac MRI image of RV  
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Figure 5: Exercise capacity in adults with congenital heart disease 
  
Adapted from Kempny A, Dimopoulos K, Uebing A, et al. Reference values for 
exercise limitations among adults with congenital heart disease. Relation to 
activities of daily life single centre experience and review of published data. Eur 
Heart J. 2012;33(11):1386-1396. doi:10.1093/eurheartj/ehr461. 
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Figure 6: Indications for Pulmonary Valve Replacement 
Abbreviations: EDP: end diastolic pressure; ESP: end systolic pressure; LV: left 
ventricle; RV: right ventricle; RVOT: right ventricular outflow tract; TOF: Tetralogy of 
Fallot  
Symptomatic  
 Decreased exercise tolerance not explained by alternate causes, lung disease, 
obesity, genetics, exercise testing (achieve < 70% peak VO2 for age and sex) 
 Signs or symptoms of heart failure 
 Syncope attributable to sustained ventricular tachyarrhythmia  
 Severe PR and/or stenosis (RV ESP > 60mmHg, TR velocity > 3.5 m/s)  
Asymptomatic + 2 of:  
 Progressive RV dilatation, RV EDV index > 150 ml/m2 or RV/LV EDV ratio > 2 
 Progressive RV dysfunction, RV EF < 47% or LV EF < 55% 
 Large RVOT aneurysm or RVOT obstruction with RV systolic pressure > 
80mmgHg (TR velocity > 4.3 m/s) 
 Progressive TR (at least moderate) 
 QRS > 160 ms 
 Sustained atrial or ventricular tachyarrhythmia 
 Hemodynamic instability secondary to RVOT obstruction, severe branch 
pulmonary stenosis, L to R shunt with Qp: Qs > 1.5, severe aortic regurgitation 
Special consideration 
 TOF repair at greater than 3 years of age 
 Women at risk of pregnancy with severe RV dilation or dysfunction 
  
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Figure 7: Right sided endocarditis 
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Figure 8: Prevalence of Arrhythmias with age 
 
Adopted from Khairy P, Aboulhosn J, Gurvitz MZ, et al. Arrhythmia Burden in Adults 
With Surgically Repaired Tetralogy of Fallot: A Multi-Institutional Study. 
Circulation. 2010;122(9): 872. 
 
Abbreviations: IART: intraatrial reentrant tachycaridia; AF: atrial fibrillation: VT: 
ventricular tacyhcardia; VT: ventricular fibrillation 
